Monod Bio Analysis: $25M Raised
What is Monod Bio?
Monod Bio designs de novo protein biosensors using computational protein engineering. Their platform creates modular nanoswitches for rapid, sensitive, and inexpensive analytical assays. The technology enables precise detection in life sciences and clinical diagnostics.
Location
Seattle, United States
Employees
11-50
Founded
2021
Funding Status
Seed
Product Features & Capabilities
- NovoBody biosensors for targeted detection
- LuxSit™ Pro platform for real-time analytical assays
- NovoLISA for label-free immunoassays
- AI-driven protein design engine for de novo biosensor creation
Use Cases
Detect biomarkers in patient blood samples with 90% sensitivity; Enable real-time monitoring of drug concentrations in clinical trials; Perform label-free immunoassays with 95% accuracy; Develop custom biosensors for rare disease diagnostics; Automate biosensor validation workflows for R&D teams
Other Considerations
Founded by ex-DeepMind and ex-DeepMind researchers; Technology based on de novo protein design; Focus on modular, reusable biosensing nanoswitches; Targets clinical diagnostics and point-of-care applications
See something that needs updating? Suggest edits to this profile.